Objective To explore the measures in early diagnosis and treatment for venous thromboembolism(VTE)in patients with fracture.Methods All the patients with fracture visiting Beijing Jishuitan Hospital in emergency during October 2004 to October 2007 were screened by Well's prediction rules,and anticoagulation and thrombolysis were instituted for those with established diagnosis of VTE by color Doppler ultrasonography and venography.Results Totally,1 508 patients at higg-risk of VTE were identified by D-dimer test.1 455 by color ultrasonography and 53 by venography.Diagnosis of VTE was established in 652 of them(43.2%),619(94.9%)received anticoagulant treatment,162(24.8%)received anticoagulant plus thrombolytie treatment and 25 (3.8%) received anticoagulation plus thrombectomy.In order to prevent fatal pulmonary embolism,vena cava filters(VCFs)were implanted in 146(22.4%)patients,and 33(5.1%)of them were contraindicated to anticoagulation.After treatment,412 cases were cured and 240 were improved,with no one failed.Conclusions Patients with fracture are at high-risk of VTE and should be screened by D-dimer test and color Doppler ultrasonography based on Well's evaluation,as well as by venography for confirming the diagnosis of VTF as appropriate.Anticoagulation and thrombolysis are still the treatment of choice,with thrombectomy and VCF implantation performed only if necessary.

Objective]To study Xin'an physician Wu Cheng asthenic diseases related theory of ideas in Bujuji, in order to more comprehensively understand asthenic diseases,to broaden the thinking, enhance the clinical curative effect. [Method]From the academic source of asthenic diseases , syndrome differentiation and treatment,prescription medication,clinical academic value, make research on Wu's thought about asthenic diseases treatment. [Result]Wu Cheng combined with their own perception and experience of clinical evidence, first put forward“external damage caused by asthenic diseases”;Aiming at the asthenic diseases of the treatment,Wu Cheng creatively put forward“support solution method”, “supplementary care method”, “treatment of spleen yin”;Wu Cheng's life was exploring the asthenic diseases,the theory of asthenic diseases had good clinical academic value,not only for the development of the cause of disease theory,but also enriching the theory of health prevention.[Conclusion]Wu Cheng Bujuji rich in content and its syndrome differentiation of asthenic diseases, with much experience, as today, treatment based on the thought of clinical asthenic diseases treatment still has important guiding significance.

Humans ; Vertigo

Humans ; Olfaction Disorders ; genetics ; Smell ; genetics

Anthropometry ; Female ; Humans ; Male ; Postural Balance ; Vision, Ocular ; Young Adult

Genetic Predisposition to Disease ; Humans ; Olfaction Disorders ; congenital ; genetics

Acute Disease ; Adolescent ; Adult ; Drugs, Chinese Herbal ; therapeutic use ; Ethylene Dichlorides ; poisoning ; Female ; Glucocorticoids ; therapeutic use ; Humans ; Male ; Middle Aged ; Poisoning ; drug therapy ; Retrospective Studies ; Treatment Outcome ; Young Adult

Antigens, Neoplasm ; genetics ; metabolism ; Breast Neoplasms ; enzymology ; genetics ; metabolism ; DNA Topoisomerases, Type II ; genetics ; metabolism ; DNA-Binding Proteins ; genetics ; metabolism ; Female ; Gene Expression Regulation, Neoplastic ; physiology ; Humans

Resistance is one of the most important reasons that restrict the clinical application of most chemotherapeutic medicines. Docetaxel is a very widely applicated antitumor medicine. Most of the researches on the mechanism of resistance against docetaxel focused on the drug transporters, changes in drug metabolism and pathway alteration of cell cycle and apoptnsis. The mechanism of docetaxel resistance and the predictive data based on clinical research to docetaxel therapy in cancer treatment were reviewed.

Gastric cancer is the fifth most common cancer and the third leading cause of death globally .Apart from the suc-cessful phase Ⅲclinical trial of trastuzumab and Ramucirumab , other targeted therapies in gastric cancer ( GC) have fallen short or still in early clinical development .In this review, we will summarize the most up to date information on many of the potential actionabledriver genesin gastric cancer and the importance of using the optimal diagnostic test to select for these molecularly defined patients . We focus on the following aspects:HER-2, EGFR, FGFR, MET, IGF-1R and VEGF.